TriangleNCT01355705 · OUTCOME
Time-to-next Treatment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- 9 months
Groups in this outcome
Amrubicin + Lenalidomide + Dexamethasone
Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles. Concurrent therapeutic medications: * Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14 * Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15) Other drugs: * Aspirin: 81 or 325 mg daily oral * Pegfilgrastim subcutaneous on Day 2
| Group | Source count |
|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 92 | Not reported | 24 | 281 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 24
- upper Limit
- 281
- value
- 92
- denoms
- counts
- group Id
- OG000
- value
- 13
- units
- Participants
- dispersion Type
- Full Range
- groups
- description
- Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles. Concurrent therapeutic medications: * Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14 * Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15) Other drugs: * Aspirin: 81 or 325 mg daily oral * Pegfilgrastim subcutaneous on Day 2
- id
- OG000
- title
- Amrubicin + Lenalidomide + Dexamethasone
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 9 months
- title
- Time-to-next Treatment
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice